A Phase I, Open Label, Randomised, Parallel Group Study of Repeated Oral Doses of AZD1981 (100 mg Twice Daily and 400 mg Twice Daily) for Two Weeks and Single Doses of Warfarin (25 mg) to Evaluate the Pharmacokinetic Interaction of AZD1981 and Warfarin and the Effect of AZD1981 on Warfarin Pharmacodynamics in Healthy Male Volunteers.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs AZD 1981 (Primary) ; Warfarin
- Indications Asthma; Atrial fibrillation; Chronic obstructive pulmonary disease; Embolism and thrombosis
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 24 Aug 2016 Results published in the British Journal of Clinical Pharmacology
- 08 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.